AI body scans could make chemo safer for women with ovarian and endometrial cancer
NCT ID NCT07144618
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether using an AI tool to analyze a patient's body composition from a CT scan can help doctors personalize chemotherapy dosing. The goal is to reduce severe side effects like low white blood cell counts in women with endometrial or ovarian cancer. About 294 participants will be randomly assigned to receive either standard dosing or AI-assisted dosing, and researchers will compare side effects, quality of life, and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Paclitaxel (chemotherapy)
- What this could lead to
- If successful, this could lead to a more personalized way to dose chemotherapy, reducing severe side effects like low white blood cell counts and improving quality of life for patients.
- What could go wrong
- This is an early-stage study (Phase NA) with 294 participants, so results may not apply to all patients. The AI tool's predictions might not consistently outperform standard dosing, and the study focuses on specific cancers and chemotherapy drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 294 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Able to comprehend and willing to participate in this clinical trial, with signed informed consent. 2. Underwent an abdominal computed tomography (CT) scan within three months prior to surgical treatment, with a non-contrast-enhanced single-slice image at the third lumbar vertebral level available for body composition analysis. 3. Histologically or cytologically confirmed diagnosis of endometrial cancer or ovarian cancer. 4. Age between 20 and 80 years. 5. Good performance status (ECOG performance status of 0, 1, or 2). 6. Adequate hematologic parameters: * Hemoglobin ≥10 g/dL * White blood cell count ≥3,000/μL * Neutrophil count ≥1,500/μL * Platelet count ≥100,000/μL 7. Adequate organ function: * Total bilirubin ≤1.5 times the upper limit of normal (ULN). * Alanine aminotransferase (ALT) / Aspartate aminotransferase (AST) ≤2.5 times ULN (≤5.0 times ULN for patients with liver metastases). * Creatinine ≤ ULN. Exclusion Criteria 1\. Presence of other major diseases that may be exacerbated by chemotherapy (e.g., autoimmune diseases). 2\. History of other malignancies within the past two years before trial enrollment, except for adequately treated non-melanoma skin cancer, stage 0 cervical carcinoma, or ductal carcinoma in situ of the breast. 3\. Requirement for concurrent treatment of unrelated diseases during the trial period, including chemotherapy, radiotherapy, or investigational drugs. 4\. Mental status deemed unsuitable for participation in the clinical trial. 5. Expected survival time of less than six months. 6. Poor-quality abdominal CT images, clearly attributable to the following causes: * Motion artifacts due to poor patient compliance. * Noticeable scoliosis or kyphosis. * Multiple lumbar vertebral compression fractures. * Significant generalized edema. * Presence of metallic implants in the lumbar spine or abdomen. * Abdominal stoma or significant abdominal wall defects. * Marked asymmetry or localized atrophy/deficiency of the core abdominal musculature.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can hormone pills replace chemo for aggressive endometrial cancer?
- Triple oral drug combo targets two stubborn gynecologic cancers
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues
- New PET tracer aims to light up hidden cancer targets